JERUSALEM, Oct. 26, 2011 /PRNewswire/ -- The following is a letter to shareholders from Ophir Shahaf, CEO of Hadasit Bio-Holdings, Ltd. (OTCBB: HADSY), a publicly traded portfolio of biotech companies based on intellectual property developed and owned by Hadassah University Hospital.
Dear Fellow Investors,
Hadasit Bio-Holdings is celebrating six years since its establishment by the Hadassah University Hospital and its IPO which made public participation in leading biotechnological developments, based on the scientific and medical knowledge and experience of the Hadassah institution, possible.
Over the years, many emerging companies have turned to public markets for financing and the general public has been more exposed to the world of biotechnology and medical developments as a result. During this time, we have had strong business and clinical progress in our portfolio and the value of our subsidiary companies has grown significantly. That said, the economy and overall market have provided its fair share of challenges.
Similar to 2008, we are witnessing the upheavals occurring in the global economy which are impacting the financial markets in particular. Despite economic conditions, the standard of medical treatment around the world continues to improve. As such, world life expectancy is on the rise, resulting in a rise in disease. In light of these trends, pharmaceutical companies are continuing their research efforts, and capital investments are driving the improvement of existing developments as well as propelling the introduction of new ones. Hadasit Bio-Holdings is taking part in this effort as well while enjoying its strong market position – a point worth making as the scientific base and the developmental abilities of Hadasit's portfolio companies have remained strong. Hadassah is world-renown in the fields of Oncology, Tissue Engineering, Autoimmune Diseases and continues to be a leading center of medic
|SOURCE Hadasit Bio-Holdings Ltd.|
Copyright©2010 PR Newswire.
All rights reserved